SAN FRANCISCO, Feb. 15 /PRNewswire/ -- Epiphany Biosciences Inc. announced today that preeminent biochemist and structural biologist Roger D. Kornberg, PhD is joining the Epiphany Scientific Advisory Board (SAB). Dr. Kornberg is a professor of structural biology and the Mrs. George A. Winzer Professor of Medicine at the Stanford University School of Medicine where his research is focused on understanding the fundamental workings of gene regulation. Prof. Kornberg was awarded the 2006 Nobel Prize in Chemistry for his studies of the molecular basis of eukaryotic transcription, the biological process by which genetic information from DNA is copied to RNA.
Prof. Kornberg obtained his PhD from Stanford University and did his postdoctoral studies with Aaron Klug and Francis Crick at the Medical Research Council (MRC) Laboratory of Molecular Biology in Cambridge (UK) where he discovered the nucleosome. His Nobel Prize-winning work included discovery of Mediator, a protein complex required to facilitate gene transcription, as well the solution of the three-dimensional crystal structure of RNA polymerase II, the most complex protein structure solved to date.
“I’m looking forward to joining a very distinguished and accomplished group of scientists as part of Epiphany’s SAB. The diversity of the Epiphany therapeutic pipeline is exciting and I look forward to helping the company translate its unique vision into products that significantly impact human health,” said Prof. Kornberg.
“We are delighted that Prof. Kornberg is joining the Epiphany SAB,” noted Epiphany founder and CEO Fred Volinsky, MD. “He has been a pioneer in elucidating some of the most complicated and fundamental processes in biology. His insight into the basic mechanisms of disease will be instrumental to Epiphany’s drug discovery and development efforts.”
“With the addition of Prof. Kornberg, Epiphany has assembled a truly world-class team of scientists and clinicians, including co-founder Dr. Robert Gallo, co-discoverer of HIV and HTLV. We believe their involvement validates Epiphany’s drug development philosophy and our mission to bring life improving therapies to patients with acute and chronic disease,” stated COO and co-founder, Dr. David Myles.
About Epiphany Biosciences
Epiphany Biosciences is focused on advancing new therapies for infectious disease. Epiphany’s team includes a world-class group of virologists. The founders include Fred Volinsky, MD, Robert Gallo MD, David Myles PhD and Barry Selick PhD. Epiphany is located in San Francisco, California. Additional information on Epiphany Biosciences may be obtained at the company website http://www.epiphanybio.com or by contacting company representatives: Fred G. Volinsky MD, CEO 415.765.7193; David C. Myles PhD, COO 415.765.7198.
Epiphany Biosciences Inc.
CONTACT: Fred G. Volinsky, MD, CEO, +1-415-765-7193, or David C. MylesPhD, COO +1-415-765-7198, both of Epiphany Biosciences Inc.
Web site: http://www.epiphanybio.com//
